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Potential synergistic interaction between gemcitabine (GEM) and epirubicin (EPI) in pancreatic cancer have been described
previously. The maximum-tolerated dose in this trial was GEM 1000mgm
 2 and EPI 45mgm
 2. Median time to progression was 5.1
months and median survival time 7.4 months. This combination appears well tolerated and shows promising clinical activity.
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Pancreatic cancer is one of the most aggressive human cancers
with an extremely poor prognosis. In 1998, gemcitabine (GEM)
was approved for use in the palliative treatment approach (Burris
et al, 1997). However, even with GEM, monotherapy has obvious
limitations in advanced pancreatic cancer and various combina-
tions with other agents have been investigated in phase III trials as
well (Burris, 2005).
In vitro studies in solid tumour cell lines have demonstrated that
pretreatment of cancer cells with the anthracycline epirubicin
(EPI), followed by administration of GEM, inhibits proliferation
and increases the rate of DNA fragmentation (Angelucci et al,
1997). The aim of this study was to find the maximum-tolerated
dose (MTD) of EPI in combination with GEM in pancreatic
carcinoma. We also sought to evaluate the antitumour activity and
the clinical benefit of this combination.
MATERIALS AND METHODS
Patient eligibility
Patients with unresectable pancreatic carcinoma with or without
distant metastases were eligible for the trial. Eligibility criteria
included age 18–75 years, Karnofsky’s performance status (KPS)
X60 and a left ventricular ejection fraction measured by multiple
electrocardiogram-gated radionuclide study (MUGA-scan) higher
than 50%. Baseline laboratory requirements were defined as
described elsewhere (Hess et al, 2003). The study was carried out
in accordance with the Declaration of Helsinki and approved by
the local ethics committees; written informed consent was
obtained from all patients.
Treatment
Gemcitabine (Gemzar
s, Eli Lilly, Indianapolis, IN, USA) was
administered as a 30-min i.v. infusion on days 1 and 8; EPI
(Pharmacia, Erlangen, Germany) as an i.v. bolus injection over a
period of 5min prior to GEM on day 8 of each 21-day cycle.
In phase I the dose escalation to a maximum of six levels consisted
of: Step 1: GEM 800mgm
 2, EPI 35mgm
 2 until Step 6: GEM
1000mgm
 2, EPI 90mgm
 2.
Toxicity score
Dose-limiting toxicity was defined, using the World Health
Organization (WHO) criteria (Miller et al, 1981). Complete blood
cell counts were measured at days 1, 8 and 15 of each 21-day cycle.
Maximum-tolerated dose for phase I of gemcitabine and
epirubicin
An open-label, phase I trial design with a standard dose escalation
schedule was used to determine the MTD. The MTD was defined as
the highest safely tolerated dose where at most one patient
experienced dose-limiting toxicity (DLT) with the next higher dose
having at least two patients who experienced DLT. A DLT was
defined as described elsewhere (Van Putten et al, 2000). Patients
enrolled in cohorts of three. If no patients in a cohort experienced
DLT in the first two cycles, escalation proceeded to the next higher
dose level. If one of the first three patients experienced a DLT,
three additional patients were added in that cohort. If no
additional DLT’s occurred, escalation continued. The MTD
represents the dose recommended for the phase II trial.
Assessment of safety, efficacy and quality of life
Adverse events reported according to the standard World Health
Organization (WHO) criteria were used for safety assessment
(Miller et al, 1981). Evaluation of tumour response was conducted
according to standard WHO criteria. A responder was defined as
any patient who had a complete or partial response, which was
confirmed by a second evaluation with the same imaging
technique at least 4 weeks later. Quality of life was measured with
a standardised and validated questionnaire (Spitzer Quality of Life
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sIndex) and clinical benefit response was defined as in the study by
Burris et al (1997).
Statistical analysis
Toxicity and efficacy were summarised by descriptive statistics.
The tumour response was presented as percentage along with the
95% confidence interval (CI). The significance level for each
hypothesis test was 5%. Median time to progression and overall
survival time was calculated according to the Kaplan–Meier
product-limit method. Subgroups were compared using the log-
rank test.
RESULTS
Between May 2000 and 2003, a total of 40 symptomatic patients
were enrolled in the study (Table 1). A total of 230 cycles of
chemotherapy was administered with a median of six cycles per
patient (range 2–9).
Three patients were entered at each dose level 1, 2 and 3 in the
phase I part. Six patients were assigned to dose level 4. At that dose
level, two of six patients experienced DLT, which consisted of
grade 3 neutropenia and anaemia in one patient and a febrile grade
4 neutro- and thrombocytopenia in a second patient. Therefore,
dose level 3 (GEM 1000mgm
 2 and EPI 45mgm
 2), was found to
be the MTD for the phase II part. Overall, 28 patients were treated
with GEM 1000mgm
 2 and EPI 45mgm
 2.
Toxicity
Haematological toxicity observed in the phase I part is shown in
Table 2. Nonhaematological toxicity in these patients was mainly
mild nausea/vomiting (grade 1/2). Two patients had grade 3
alopecia and mild gastrointestinal toxicity (diarrhoea) occurred in
four patients. Five patients (33%) experienced grades 1 and 2
mucositis, but this was manageable in all patients. A dose reduction
was necessary in four patients, three of whom were treated at dose
level 4. Renal, hepatic and neurologic toxicities were generally mild
and no evidence of cardiac toxicity was recorded.
Overall, the 28 patients who were treated with the MTD of GEM
1000mgm
 2 and EPI 45mgm
 2 experienced only mild toxicity.
Grade 3 haematologic toxicity occurred in one patient of phase I
(anaemia) and one patient of phase II (neutropenia). In seven
(25%) patients dose reduction of both drugs to 75% was necessary
while one patient received dose reduction to 50% due to
leukopenia grade III in one cycle, and treatment delay for 1 week
in another cycle.
One patient at this dose level experienced grade 3 nausea/
vomiting. Chemically induced phlebitis due to EPI was noted only
in one other patient. Hospitalisation was necessary for another
patient due to pneumonia. No major hepatic, renal, cardiac and
neurologic toxicities were seen as well (Table 3).
Tumour response and survival
The overall response rate was 23% (95% CI: 0.29–0.62) based on
nine of 40 patients with partial response. The median time to
response was 3 (range 2.5–3.7) months, and the median duration
of response was 8.2 (range 4–12) months. Stable disease (SD)
occurred in 14 of 40 (35%) patients. The remaining 17 (42.5%)
patients showed progressive disease. Median time to disease
progression for all patients was 4.2 (range 2–12) months.
The 6 months and 1-year survival rates were 55% (22/40
patients) and 22.5% (9/40 patients), respectively. The median
overall survival time was 7.4 (range 2–21.8) (95% CI: 5.1–9.9)
months. For patients with tumour response (9/40 patients), the
median survival was 12.6 (range 10.7–21.8) months, and the
probability of surviving beyond 1 year was 55%. Patients with
objective tumour response survived significantly longer than
patients with no tumour response (P¼0.01).
Clinical benefit response
Thirty-seven patients with tumour-related symptoms were con-
sidered evaluable for clinical benefit response. In 10/35 (29%)
patients suffering from pain at study entry, pain intensity and/or
analgesic use was reduced at least by 50% compared to baseline
values, and 18 remained stable in this category. Improvement of
KPS occurred in 13 (35%) patients and performance status
Table 1 Pretreatment characteristics
Characteristics N (%)
Number of patients 40
Age, median/range (years) 67.578.5 (43–75)
Gender (F/M) 16/24 (40/60)
Karnofsky performance status (KPS)
X60 8 (20)
70–80 25 (62.5)
90–100 7 (17.5)
Disease stage at presentation
Stage III 13 (32)
Stage IV 27 (68)
Histological grade
G 1 3 (7.5)
G 2 26 (65)
G 3 11 (27.5)
Prior surgery
None 24 (60)
Explorative laparotomy 10 (25)
Palliative bypass 6 (15)
Table 2 Haematological toxicity (number of patients) in the phase I part
of the study
WHO toxicity Leucocytes Granulocytes Haemoglobin Platelets
Level 1
0–1 0 2 3 3
23 1 0 0
30 0 0 0
40 0 0 0
Level 2
0–1 2 1 2 3
21 2 1 0
30 0 0 0
40 0 0 0
Level 3
0–1 1 2 1 3
22 1 1 0
30 0 1 0
40 0 0 0
Level 4
0–1 4 2 3 3
20 2 2 2
31 1 1 0
41 1 0 1
Level 1: GEM 800mgm
 2+EPI 35mgm
 2; Level 2: GEM 800mgm
2+EPI
45mgm
 2; Level 3: GEM 1000mgm
 2+EPI 45mgm
 2; Level 4: GEM
1000mgm
 2+EPI 60mgm
 2.
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patients (21.6%) had a weight gain of X7% from baseline during
the study. Improvement of the quality of life during treatment
measured and expressed with the Spitzer-activity-index was seen
in 15 of 37 (40.5%) patients. In the final assessment, a total of 18
patients were classified as clinical benefit responders, yielding a
clinical response rate of 49% (95% CI: 0.29–0.62). We observed a
significant correlation between clinical benefit response and
objective tumour response as well (Po0.001).
DISCUSSION
Our experience with GEM and EPI clearly demonstrated that this
combination is adequately tolerated with moderate toxicities that
were qualitatively and quantitatively similar to those reported from
other trials (Scheithauer et al, 1999; Neri et al, 2002; Reni et al,
2005).
In line with the preclinical observation of synergy, the
combination of GEM and EPI achieved a promising preliminary
antitumour effect. In this trial, we achieved a 22.5% overall
remission rate in 40 evaluable patients and a median response
duration of 8 months. With an additional 35% of patients
experiencing SD this combination achieved a favourable disease
control in almost 60% of patients. Three other GEMþEPI studies
in pancreatic cancer have been published in manuscript form
(Scheithauer et al, 1999; Neri et al, 2002; Reni et al, 2005).
Concerning objective tumour response and disease control, the
reported data are comparable (objective response 21–51%; disease
control 65–80%) with our results. Neri et al (2002) reported an
overall response rate of 25% and a SD in 41% of their patients.
Most patients (77%) in that study were stage IV and two-thirds had
a mean KPS between 70 and 80.
Comparable objective results were published by Scheithauer
et al (1999) with a combination of GEM 1000mgm
 2þEPI
60mgm
 2þgranulocyte colony-stimulating factor. Recently, a
phase III trial with GEM in combination with EPI, 5-FU and
cisplatin vs GEM was published by Reni et al (2005). They found
an overall response of 38.5% and stabilisation of the disease in
further 28.8% with the combination therapy. Overall, these data
from GEMþEPI trials supports the hope that some improvements
in response rates and prognosis may be achievable.
In our study, we observed a clinical benefit response in 49% of
symptomatic patients. This compares favourably with the rate of
clinical benefit response in the GEMþEPI studies by Scheithauer
et al (1999) (43%) and Neri et al (2002) (44%). However, using the
same validated definitions for clinical benefit response, there is
almost a doubling of the rate of clinical benefit responders with the
combination therapy in comparison with GEM alone (Burris et al,
1997, Neri et al, 2002).
In conclusion, this combination chemotherapy of GEM and EPI
was well tolerated and feasible at the recommended dose level. The
regimen is active with a high rate of clinical benefit responders.
Whether addition of EPI to GEM is comparable to the combination
of other drugs (cisplatin, irinotecan, 5-FU, and ‘biologicals’) and
GEM should be further evaluated in randomised phase III trials.
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Table 3 Summary of maximum treatment-associated toxicities (n¼25)
in the phase II part of the study
Number of patients/WHO-toxicity grade (%)
Toxicity 1 2 3 4
Haematological and other laboratory-based toxicity
Leukopenia 3 (12) 4 (16) 1 (4) 0
Granulocytopenia 2 (8) 3 (12) 1 (4) 0
Thrombocytopenia 0 0 0 0
Anaemia 3 (12) 1 (4) 0 0
Bilirubin 1 (4) 0 0 0
Alkaline phosphatase 3 (12) 1 (4) 0 0
Serum transaminases 3 (12) 0 0 0
Symptomatic toxicity
Nausea/vomiting 4 (16) 1 (4) 1 (4) 0
Stomatitis 2 (8) 0 0 0
Diarrhoea 2 (8) 0 0 0
Constipation 1 (4) 0 0 0
Infection 1 (4) 0 1 (4) 0
Fever 2 (8) 0 0 0
Alopecia 4 (16) 1 (4) 1 (4) 0
Cutaneous 0 0 0 0
Phlebitis 1 (4) 1 (4) 0 0
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